Navigation Links
Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
Date:7/18/2012

BOSTON, July 18, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) today announced a new research collaboration with Brigham and Women's Hospital (BWH), a teaching and research affiliate of Harvard Medical School, focused on immunology of type 1 diabetes. The two organizations will share knowledge and apply their respective expertise in basic and applied research regarding diabetes and drug target and candidate development. 

(Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO )

Under the terms of the agreement, researchers from both organizations will undertake proof-of-concept, safety and functional studies for a novel immunomodulatory approach to treat type 1 diabetes. Sanofi has an option to exclusively license intellectual property emerging from this collaboration.

"Our engagement in this important research collaboration exemplifies our aim to help identify new treatment options and ultimately bring real benefits to people with type 1 diabetes," commented Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "By working together to translate academic knowledge into know-how about a potential new drug target, we hope to discover revolutionary new options for patients living with type 1 diabetes worldwide."

Diabetes affects nearly 26 million people in the U.S. alone, with an estimated global prevalence of 346 million people(1,2) - a number which the World Health Organization projected would double between 2005 and 2030. In diabetes the body does not produce enough insulin, a hormone that regulates blood sugar, or cannot properly utilize the insulin it does make. It is the leading cause of kidney failure, a major cause of heart disease and stroke, and the seventh leading cause of death in the U.S.(1)

"Brigham and Women's Hospital is excited to e
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
5. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
6. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
7. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
8. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. Agendia Signs Contract with Blue Shield of California
11. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 This report ... Quartz Tubing industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... tubing industry has witnessed rapid development with ... of acquisitions. This report mentions quartz tubing upstream ...
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... the Basque Country (Spain) has developed a method to ... and suspected to be explosive. Some of the samples ... and boric acid. Each year police forces seize ... indoor firework manufacturing (i.e. flares or those used in ...
... that affects about one in four military veterans of the ... which differed in importance depending upon the locations where veterans ... , Published online today in the journal ... and veterans, locations during the war. GWI was most ...
... recycling of "old" processes and protocols that were once ... settings, but which can now be applied to nano-sized ... instruments and know-how., After several years of research, scientists ... Emir Gonzlez (currently at Instituto Geofsico Universidad Javeriana y ...
Cached Biology Technology:Are those liquids explosive? 2Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study 2Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study 3
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... COLLEGE STATION The U.S. Department of Energy has granted more ... fuel source. And if that succeeds within 18 months, almost $2 million ... fast-growing grass species. , ... our country is the leader around the world in terms of energy ...
... fishermen would not give up their livelihood in the face ... University of East Anglia (UEA). A new report, published ... about poverty and adaptation by investigating why fishermen in developing ... Daw from UEA,s School of International Development and the Stockholm ...
... 2012 Aware, Inc. (NASDAQ: AWRE ), a ... today reported financial results for its fourth quarter and year ... fourth quarter of 2011 was $5.9 million, a decrease of ... year. Net income for the fourth quarter of 2011 was ...
Cached Biology News:US Energy Department grants $1.87 million for plant fuel project 2University of East Anglia research reveals why fishermen keep fishing despite dwindling catches 2University of East Anglia research reveals why fishermen keep fishing despite dwindling catches 3Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 2Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 3Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 4Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 5
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
Biology Products: